uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
163.41 56.70 85.48 216.85
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(106.77) (26.82) (17.74) (208.28)
P/B ratio
9.42 6.87 6.92 14.93
EV/Sales
123.14 27.50 50.40 176.59
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(14.05) (2.85) (4.49) (17.85)
Current Ratio
10.01 10.40 10.43 7.12
Net Debt/EBITDA
16.07 12.55 11.90 13.55
Debt/Equity
0.15 0.33 0.25 0.23
Earnings Yield
(8.71%) (21.28%) (14.42%) (7.52%)
Free Cash Flow Yield
(5.36%) (17.04%) (13.13%) (4.56%)
Free Cash Flow per Share
(0.44) (0.61) (1.35) (0.28)
Book value per Share
4.89 2.38 3.46 3.91
Free Cash Flow
(29.05) (38.38) (77.69) (16.33)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates